Core Viewpoint - The article highlights the strong performance and liquidity of the Science and Technology Innovation (Sci-Tech) Pharmaceutical ETF managed by Harvest, indicating significant growth in both trading volume and fund shares over the past year [2][4]. Group 1: Liquidity and Trading Performance - The Sci-Tech Pharmaceutical ETF by Harvest recorded a turnover rate of 15.19% during trading, with a transaction volume of 30.598 million yuan, reflecting active market participation [2]. - As of July 25, the average daily trading volume over the past week was 46.0799 million yuan, ranking first among comparable funds [2]. - The fund's shares increased by 67.5 million over the past year, also ranking first among comparable funds [2]. Group 2: Fund Performance and Returns - The net value of the Sci-Tech Pharmaceutical ETF increased by 52.17% over the past year, placing it in the top 16.41% among 2,938 index equity funds [2]. - Since its inception, the fund achieved a maximum monthly return of 23.29%, with the longest consecutive monthly gains lasting 5 months and a maximum cumulative increase of 23.50% [2]. - The average return during the months of increase was 7.43% [2]. Group 3: Key Holdings and Market Outlook - As of June 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 50.3% of the index, with leading companies including United Imaging Healthcare, BeiGene, and Huatai Medical [2][4]. - Based on the current fundamentals of the pharmaceutical sector, which has undergone four years of adjustment, the market outlook suggests a positive trend for innovative drugs and the overall pharmaceutical sector [4][5]. - The recommendation is to focus on innovative drugs as the primary investment theme, while also considering sectors like CRO&CDMO and specialty raw materials that are expected to perform well [5].

Investment Rating - The report maintains a positive outlook on innovative drugs and the industry chain, recommending continuous attention to this sector [1][5][24]. Core Viewpoints - The report highlights the sustained high prosperity of innovative drugs, with a focus on companies likely to see a revaluation, such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, and Huadong Medicine. It also emphasizes Biopharma/Biotech companies with innovative pipelines entering a growth phase, including PATEO, Innovent Biologics, BeiGene, and others [1][5][24]. - The A-share pharmaceutical sector outperformed the market in the third week of July 2025, with a 4.0% increase compared to a 0.7% rise in the Shanghai Composite Index. The report notes that the premium of the pharmaceutical sector relative to all A-shares is currently at a normal level of 86.8% [7][25][16]. - The Hong Kong pharmaceutical sector showed outstanding performance, with the Hang Seng Healthcare index rising by 12.0% and the Hong Kong Biotechnology index increasing by 13.6% during the same period [21][25]. Summary by Sections 1. Continuous Focus on Innovative Drugs and Industry Chain - The report emphasizes the ongoing high demand for innovative drugs and recommends companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others for potential investment [1][5][24]. 2. Performance of A-Shares Pharmaceutical Sector - In the third week of July 2025, the A-share pharmaceutical sector led with a 4.0% increase, outperforming the overall market. Notable sub-sectors included chemical raw materials and chemical preparations, with gains of 7.0% and 6.8% respectively [7][11][25]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector performed exceptionally well, with significant gains in the Hang Seng Healthcare and Biotechnology indices. In contrast, the U.S. pharmaceutical sector underperformed, with a decline of 2.5% in the S&P 500 Healthcare Select Sector [21][25].

Group 1: ETF Performance - The liquidity of the Kexin Pharmaceutical ETF managed by Jiashi showed a turnover rate of 16.97% with a transaction volume of 33.88 million yuan, indicating active market trading [2] - Over the past year, the Kexin Pharmaceutical ETF has seen a significant growth in scale, increasing by 119 million yuan, ranking first among comparable funds [2] - The net asset value of the Kexin Pharmaceutical ETF has risen by 48.37% over the past year, placing it in the top 15.05% among index equity funds [2] Group 2: Stock Performance - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading stocks including United Imaging Healthcare and BeiGene [2] - Recent stock performance includes United Imaging Healthcare with a rise of 2.04% and BeiGene with a slight increase of 0.21%, while Huatai Medical saw a decline of 2.71% [4] Group 3: Industry Trends - The biopharmaceutical industry is entering a dual-driven phase of policy and technology, with innovation drug support policies advancing to phase 2.0 [5] - The medical device sector is experiencing a core trend of replacement and technology export, with regulatory upgrades promoting innovation and industry breakthroughs [5] - State-owned capital entering the biopharmaceutical sector is injecting financial vitality, accelerating R&D investment and industry chain integration [5] Group 4: Licensing Agreements - Chinese innovative pharmaceutical companies are reporting significant "Licence Out" transactions, with Kexin Pharmaceuticals announcing a deal with ERIGEN for an exclusive overseas licensing agreement worth up to 1.32 billion USD [4]

Core Insights - The reactivation of the fifth listing standard on the Sci-Tech Innovation Board (STAR Market) aims to support high-growth technology companies, particularly in the biopharmaceutical sector, by allowing companies without profits to list based on expected market capitalization and R&D achievements [1][19] - The biopharmaceutical industry, especially innovative drug companies, faces longer investment periods and higher uncertainty due to strict regulatory requirements for product approval, making them highly reliant on capital [1][19] - Since the reactivation in June 2025, companies like He Yuan Bio and Bei Xin Life have made significant progress, signaling a positive outlook for other biopharmaceutical firms still in clinical stages [2] Market Performance - The innovative drug sector has seen a remarkable stock performance in 2025, driven by favorable policy changes, relaxed procurement policies, and the growth of commercial health insurance, which enhances market expectations for innovative drugs [3] - The 20 companies that successfully listed under the fifth standard have achieved a total market capitalization of 364.12 billion, with an average increase of 79.10% since the beginning of 2025 [3][7] Financial Performance - In 2024, the 20 companies reported a combined revenue exceeding 14.3 billion, a year-on-year growth of 45%, with 16 companies generating over 1 billion in revenue [12][16] - The total R&D expenses for these companies accounted for 67% of their total revenue, indicating a high dependency on external financing for continued innovation [16][18] R&D and Innovation - The 20 companies listed under the fifth standard have collectively developed 45 drug varieties, with 22 classified as first-class new drugs or innovative biological products, covering various advanced therapeutic areas [8][10] - The number of candidate products in the R&D pipeline for these companies has exceeded 200, showcasing their commitment to innovation and market expansion [8] Regulatory Environment - The reactivation of the fifth standard reflects a shift in regulatory focus towards recognizing the inherent risks and long timelines associated with technology innovation, moving away from traditional financial metrics [19][20] - The introduction of a "Sci-Tech Growth Tier" aims to enhance information disclosure and regulatory oversight for companies listed under the fifth standard, ensuring a balance between support and supervision [22]

Group 1: ETF Performance - The liquidity of the Kexin Pharmaceutical ETF (嘉实) showed an intraday turnover of 18.19%, with a transaction volume of 40.9491 million yuan, indicating active market trading [3] - Over the past week, the Kexin Pharmaceutical ETF (嘉实) experienced a scale increase of 16.9597 million yuan, ranking first among comparable funds [3] - The Kexin Pharmaceutical ETF (嘉实) saw a share increase of 7.5 million shares over the past week, also ranking first among comparable funds [3] - As of July 21, the Kexin Pharmaceutical ETF (嘉实) has achieved a net value increase of 43.45% over the past year, placing it in the top 16.56% among 2,929 index equity funds [3] Group 2: Stock Performance - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading stocks including 联影医疗 (9.73%), 百济神州 (6.04%), and 惠泰医疗 (5.69%) [5][3] - The highest monthly return since inception for the Kexin Pharmaceutical ETF (嘉实) was 23.29%, with the longest consecutive monthly increase being 5 months and an average monthly return of 7.43% [3] Group 3: Market Trends - Huazhong Securities maintains a bottom-up view of the pharmaceutical sector, emphasizing the importance of hard technology innovations, particularly in innovative drugs and devices, which are becoming market hotspots [6] - The recent announcement from the Shanghai Sunshine Pharmaceutical Procurement Network regarding the 11th batch of national centralized procurement includes 55 drug varieties, with key principles focusing on stability, quality assurance, and anti-competitive practices [5]

6年前，肩负着支持科技创新"前沿阵地"与改革"试验田"的重任，科创板掀开了中国资本市场注册制改 革的新篇，重塑资本服务实体经济的底层逻辑。 6年来，汇聚起589家"硬科技"企业的科创板从未停止探索与创新的步伐。一个月前，《关于在科创板设 置科创成长层 增强制度包容性适应性的意见》（以下简称《科创板意见》）发布，为服务科技创新和 新质生产力发展再度加码。 当前，新一轮科技革命和产业变革深入发展，面对科技型企业对资本市场提出的更加多样化需求，"以 在科创板设置专门层次为抓手，重启未盈利企业适用科创板第五套标准上市"，正是科创板给出的最新 答卷。 以集成电路为例，科创板集成电路上市公司达120家，涵盖芯片设计、制造、封测、设备、材料、软件 等产业链各环节，汇聚了中芯国际、中微公司、沪硅产业等主要行业龙头，逐步形成链条完整、协同创 新的发展格局，推动提升了我国集成电路产业的自主化水平。 与此同时，一批科创板公司持续推动前沿技术发展和产业变革，面向人工智能、基因技术、量子信息等 未来产业正加快布局。当前，我国科技领域，特别是在人工智能、商业航天、低空经济等领域取得较大 突破，更大力度支持这些行业企业发展、为投资者提供分 ...

Summary of the Earnings Call for Ailis Company Company Overview - Ailis Company is focused on the development and commercialization of targeted therapies for cancer, particularly in the area of non-small cell lung cancer (NSCLC) with EGFR mutations and KRAS mutations [2][3]. Key Products and Market Performance - **Fumetinib**: - Approved for multiple indications, including first-line and second-line treatments for EGFR mutation-positive NSCLC [2][3]. - Projected sales for 2024 are 3.5 billion RMB, representing a 77% year-over-year growth [2][5]. - Clinical data shows superior progression-free survival (PFS) and objective response rates (ORR) compared to Osimertinib [2][6]. - In patients with brain metastases, the ORR is 66%, with a disease control rate of 100% and a significant reduction in the risk of disease progression or death by 60% [2][9]. - Demonstrated efficacy in treating EGFR 20 exon insertion mutations, with ORR of 78% and 46% in different dosing groups [2][10]. - **KRAS G12C Inhibitor (Glarasertib)**: - Approved in May 2025, showing an ORR of 77.9% in second-line treatment and a disease control rate exceeding 86% [2][12]. - Currently in clinical trials for first-line treatment in combination with SHIP2 inhibitors [2][12]. - **Pralsetinib**: - Recently introduced and has achieved local production, which is expected to lower costs and prices, facilitating entry into health insurance negotiations [3][4][14]. - Recommended in multiple treatment guidelines, indicating a positive sales outlook [4][14]. Financial Performance - Ailis Company reported a strong financial performance with projected revenues of 3.5 billion RMB for 2024, a nearly 80% increase year-over-year [4][5]. - Net profit is expected to reach 1.4 billion RMB, reflecting a 120% increase, with a net profit margin of 40% [4][5]. Market Dynamics - The market for EGFR mutation-positive NSCLC is expanding, with approximately 250,000 new patients annually in China [6]. - EGFR mutations account for 30% of all NSCLC cases, with a significant portion being adenocarcinoma [6]. - The introduction of third-generation TKIs like Fumetinib addresses resistance issues seen with earlier generations, enhancing patient outcomes [6][7]. Clinical Insights - Fumetinib has shown a median PFS of 20.8 months, surpassing Osimertinib's 19 months, and a high ORR of 85% [6][7]. - The drug's safety profile is favorable, with lower rates of severe adverse reactions compared to Osimertinib [7]. Future Outlook - Ailis Company is optimistic about its growth trajectory, with potential for market expansion both domestically and internationally [15]. - The product pipeline, particularly Fumetinib, is expected to drive significant revenue growth in the coming years [15].

以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 中泰证券称，目前医药板块处在一定分化加强阶段，一方面是医药跟市场其他板块的资金流向，另一方 面是医药内部成长属性的创新药，和以业绩为导向的困境反转的板块和个股。本周创新产业链的表现一 定程度反应的市场情绪和配置的变化。当前市场，我们建议两条主线共同把握：从基本面来看，创新药 仍是当前医药板块中产业趋势最为明确且具备未来成长空间的子行业，我们认为全年维度创新药作为医 药板块的投资主线不会变化，创新药大时代已然到来，建议积极拥抱，加配医药板块；此外，7 月中报 业绩预告/快报陆续披露，CRO&CDMO、GLP-1 景气赛道、困境反转的原料药等表现亮眼，我们建议 继续积极布局有望逐步走出拐点的细分板块，如CRO&CDMO、科研上游、特色原料药等。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，CS医药创新指数通过客观的量化指标，筛选出符 合前述高景气度赛道的股票，是市场上唯一一只完全基于量化因子编制的医药主题指数。 展望未来，预计我国医疗卫生支出的总盘子仍将实现稳定的可持续增长。在行业稳步扩容下，寻找快于 行业平均增速的细分领域，将成为超额 ...

Core Viewpoint - The Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index has shown strong performance, with significant increases in constituent stocks, indicating a positive trend in the biopharmaceutical sector [1][3]. Market Performance - As of July 11, 2025, the Biopharmaceutical Index rose by 1.23%, with notable gains from stocks such as Yifang Biotech (+10.31%), Shouyao Holdings (+8.34%), and Te Bao Biotech (+7.18%) [1]. - The Jiashi Science and Technology Medicine ETF (588700) also increased by 1.14%, marking its third consecutive rise [1]. Liquidity and Trading Volume - The Jiashi Science and Technology Medicine ETF recorded a turnover rate of 9.54% and a trading volume of 21.11 million yuan [3]. - Over the past month, the ETF has maintained an average daily trading volume of 33.32 million yuan, ranking first among comparable funds [3]. Fund Growth and Performance - In the last two weeks, the Jiashi Science and Technology Medicine ETF's scale increased by 17.56 million yuan, leading among comparable funds [3]. - The ETF's net value has risen by 37.70% over the past year, with a maximum single-month return of 23.29% since its inception [3]. Top Holdings - As of June 30, 2025, the top ten weighted stocks in the Biopharmaceutical Index accounted for 50.3% of the index, including companies like United Imaging Healthcare, BeiGene, and Huatai Medical [3][5]. Policy Support and Market Outlook - Recent policy documents have been released to support the high-quality development of innovative drugs, highlighting government backing for the sector [6]. - The number of innovative drugs in development in China has reached over 4,000, representing approximately 30% of the global total [5][6].

Group 1 - The core viewpoint highlights the significant growth and performance of the Kexin Pharmaceutical ETF managed by Jiashi, with a notable increase in trading volume and fund size [2] - As of July 9, the Kexin Pharmaceutical ETF achieved a daily average trading volume of 34.95 million yuan over the past month, ranking first among comparable funds [2] - The fund's size increased by 16.76 million yuan in the past two weeks, also ranking first among comparable funds [2] - The ETF saw a total inflow of 12.84 million yuan over the last ten trading days, indicating strong investor interest [2] - The net value of the Kexin Pharmaceutical ETF rose by 36.83% over the past year, showcasing its strong performance [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [2][4] - On July 9, Shanghai Pharmaceuticals announced an expected net profit of 4.45 billion yuan for the first half of 2025, representing a year-on-year increase of approximately 52% [4] Group 3 - Short-term market expectations for overseas transactions in innovative drugs are high, leading to a continuous rise in valuations [5] - China's innovative drug research and development capabilities are competitive globally, and the trend of innovative drugs going overseas is expected to persist [5] - The commercial health insurance sector in China is anticipated to see significant growth in premium income and payout rates, becoming an important source of funding for innovative drugs [5]